What is ARTIVA BIOTHERAPEUTICS INC's earnings per share (EPS)?

ARTIVA BIOTHERAPEUTICS INC (ARTV) reported diluted earnings per share of $-3.43 for fiscal year 2025. This represents a 41.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ARTIVA BIOTHERAPEUTICS INC Financials

ARTV

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows ARTIVA BIOTHERAPEUTICS INC (ARTV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 50/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth

ARTIVA BIOTHERAPEUTICS INC's revenue declined 100% year-over-year, from $251K to $0. This contraction results in a growth score of 0/100.

Leverage

ARTIVA BIOTHERAPEUTICS INC carries a low D/E ratio of 0.19, meaning only $0.19 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 8.61, ARTIVA BIOTHERAPEUTICS INC holds $8.61 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

ARTIVA BIOTHERAPEUTICS INC generates a -76.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -35.0% the prior year.

Piotroski F-Score Weak

1/9

ARTIVA BIOTHERAPEUTICS INC passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.92x

For every $1 of reported earnings, ARTIVA BIOTHERAPEUTICS INC generates $0.92 in operating cash flow (-$76.8M OCF vs -$83.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

ARTIVA BIOTHERAPEUTICS INC generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

EBITDA

-$87.2M

YoY-34.5%

ARTIVA BIOTHERAPEUTICS INC's EBITDA was -$87.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 34.5% from the prior year.

Net Income

-$83.9M

YoY-28.3%

ARTIVA BIOTHERAPEUTICS INC reported -$83.9M in net income in fiscal year 2025. This represents a decrease of 28.3% from the prior year.

EPS (Diluted)

$-3.43

YoY+41.0%

ARTIVA BIOTHERAPEUTICS INC earned $-3.43 per diluted share (EPS) in fiscal year 2025. This represents an increase of 41.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$79.3M

YoY-42.5%

ARTIVA BIOTHERAPEUTICS INC generated -$79.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 42.5% from the prior year.

Cash & Debt

$26.7M

YoY-33.6%

ARTIVA BIOTHERAPEUTICS INC held $26.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-76.3%

YoY-41.2pp

ARTIVA BIOTHERAPEUTICS INC's ROE was -76.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 41.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$69.5M

YoY+38.2%

ARTIVA BIOTHERAPEUTICS INC invested $69.5M in research and development in fiscal year 2025. This represents an increase of 38.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2.6M

YoY+303.0%

ARTIVA BIOTHERAPEUTICS INC invested $2.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 303.0% from the prior year.

ARTV Income Statement

Metric	FY25	FY24	FY23
Revenue	$0-100.0%	$251K-99.3%	$33.5M
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	$69.5M+38.2%	$50.3M+0.2%	$50.3M
SG&A Expenses	$20.3M+17.8%	$17.2M+23.7%	$13.9M
Operating Income	-$89.8M-33.5%	-$67.3M-119.4%	-$30.7M
Interest Expense	N/A	N/A	N/A
Income Tax	$0	$0-100.0%	$72K
Net Income	-$83.9M-28.3%	-$65.4M-127.6%	-$28.7M
EPS (Diluted)	$-3.43+41.0%	$-5.81+83.8%	$-35.78

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$251K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$17.6M-1.3%	$17.9M+4.7%	$17.1M	N/A	$13.5M+9.7%	$12.3M+10.6%	$11.2M
SG&A Expenses	N/A	$5.3M+6.4%	$4.9M-3.3%	$5.1M	N/A	$4.8M+24.7%	$3.9M+7.5%	$3.6M
Operating Income	N/A	-$22.9M-0.4%	-$22.8M-2.9%	-$22.2M	N/A	-$18.3M-13.2%	-$16.2M-11.7%	-$14.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$21.5M-1.3%	-$21.3M-4.6%	-$20.3M	N/A	-$17.5M+2.1%	-$17.8M-27.8%	-$14.0M
EPS (Diluted)	N/A	$-0.88-1.1%	$-0.87-4.8%	$-0.83	N/A	$-0.92+95.8%	$-22.00-27.6%	$-17.24

ARTV Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$130.9M-37.5%	$209.6M+99.4%	$105.1M
Current Assets	$112.7M-40.3%	$188.6M+136.3%	$79.8M
Cash & Equivalents	$26.7M-33.6%	$40.2M-24.8%	$53.5M
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	$0-100.0%	$1.0M
Goodwill	N/A	N/A	N/A
Total Liabilities	$21.0M-8.6%	$22.9M-91.4%	$267.1M
Current Liabilities	$13.1M+6.8%	$12.3M+0.2%	$12.2M
Long-Term Debt	N/A	N/A	N/A
Total Equity	$110.0M-41.1%	$186.6M+215.2%	-$162.0M
Retained Earnings	-$330.5M-34.0%	-$246.7M-36.1%	-$181.3M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$130.9M-12.0%	$148.9M-12.1%	$169.4M-11.4%	$191.3M-8.7%	$209.6M-7.1%	$225.6M+197.2%	$75.9M	N/A
Current Assets	$112.7M-13.0%	$129.5M-13.1%	$149.1M-12.3%	$170.0M-9.9%	$188.6M+25.3%	$150.6M+202.6%	$49.7M	N/A
Cash & Equivalents	$26.7M+4.7%	$25.5M-10.4%	$28.5M-6.4%	$30.4M-24.4%	$40.2M-28.0%	$55.9M+63.2%	$34.2M-28.9%	$48.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	$0-100.0%	$569K0.0%	$569K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$21.0M+6.8%	$19.6M-3.5%	$20.4M-9.5%	$22.5M-2.0%	$22.9M-6.7%	$24.6M-90.8%	$267.0M	N/A
Current Liabilities	$13.1M+17.7%	$11.1M+3.3%	$10.8M-11.8%	$12.2M-0.4%	$12.3M-7.8%	$13.3M+22.8%	$10.8M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$110.0M-14.9%	$129.2M-13.3%	$149.0M-11.7%	$168.8M-9.6%	$186.6M-7.1%	$201.0M+205.2%	-$191.1M-9.4%	-$174.7M
Retained Earnings	-$330.5M-6.7%	-$309.8M-7.5%	-$288.2M-8.0%	-$267.0M-8.2%	-$246.7M-7.0%	-$230.6M-8.2%	-$213.1M	N/A

ARTV Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$76.8M-39.5%	-$55.0M-16.0%	-$47.4M
Capital Expenditures	$2.6M+303.0%	$642K-80.3%	$3.3M
Free Cash Flow	-$79.3M-42.5%	-$55.7M-9.8%	-$50.7M
Investing Cash Flow	$63.4M+152.6%	-$120.5M-363.8%	-$26.0M
Financing Cash Flow	$9K-100.0%	$162.2M+565.1%	$24.4M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$14.7M+23.3%	-$19.2M+16.5%	-$23.0M-15.8%	-$19.8M-35.4%	-$14.7M-26.2%	-$11.6M+15.2%	-$13.7M+9.3%	-$15.1M
Capital Expenditures	$421K-29.8%	$600K-43.1%	$1.1M+106.5%	$511K+698.4%	$64K-33.3%	$96K-79.3%	$464K+2477.8%	$18K
Free Cash Flow	-$15.1M+23.5%	-$19.8M+17.6%	-$24.0M-18.1%	-$20.4M-38.3%	-$14.7M-25.7%	-$11.7M+17.3%	-$14.1M+6.3%	-$15.1M
Investing Cash Flow	$16.0M-1.5%	$16.3M-22.9%	$21.1M+111.8%	$10.0M+1132.2%	-$966K+99.3%	-$130.6M-9783.3%	$1.3M-86.2%	$9.8M
Financing Cash Flow	-$121K-227.0%	-$37K+48.6%	-$72K-130.1%	$239K+896.7%	-$30K-100.0%	$163.9M	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ARTV Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	-26805.6%-26714.0pp	-91.6%
Net Margin	N/A	-26045.0%-25959.3pp	-85.8%
Return on Equity	-76.3%-41.2pp	-35.0%	N/A
Return on Assets	-64.0%-32.9pp	-31.2%-3.9pp	-27.3%
Current Ratio	8.61-6.8	15.39+8.9	6.53
Debt-to-Equity	0.19+0.1	0.12+1.8	-1.65
FCF Margin	N/A	-22180.9%-22029.5pp	-151.3%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-5773.7%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-5562.9%
Return on Equity	N/A	-16.7%-2.4pp	-14.3%-2.2pp	-12.0%	N/A	-8.7%	N/A	N/A
Return on Assets	N/A	-14.5%-1.9pp	-12.6%-1.9pp	-10.6%	N/A	-7.7%+15.8pp	-23.5%	N/A
Current Ratio	8.61-3.0	11.65-2.2	13.84-0.1	13.93-1.5	15.39+4.1	11.33+6.7	4.59	N/A
Debt-to-Equity	0.19+0.0	0.15+0.0	0.140.0	0.13+0.0	0.120.0	0.12+1.5	-1.40	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-6017.5%

Similar Companies

Mink Therapeutics, Inc. INKT

$49.6M

Alx Oncology Holdings Inc ALXO

$260.6M

Celularity Inc CELU

$37.8M

Adicet Bio Inc ACET

$66.0M

Vivani Medical VANI

$84.6M

Frequently Asked Questions

What is ARTIVA BIOTHERAPEUTICS INC's annual revenue?

ARTIVA BIOTHERAPEUTICS INC (ARTV) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ARTIVA BIOTHERAPEUTICS INC's revenue growing?

ARTIVA BIOTHERAPEUTICS INC (ARTV) revenue declined by 100% year-over-year, from $251K to $0 in fiscal year 2025.

Is ARTIVA BIOTHERAPEUTICS INC profitable?

No, ARTIVA BIOTHERAPEUTICS INC (ARTV) reported a net income of -$83.9M in fiscal year 2025.

What is ARTIVA BIOTHERAPEUTICS INC's EBITDA?

ARTIVA BIOTHERAPEUTICS INC (ARTV) had EBITDA of -$87.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is ARTIVA BIOTHERAPEUTICS INC's return on equity (ROE)?

ARTIVA BIOTHERAPEUTICS INC (ARTV) has a return on equity of -76.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is ARTIVA BIOTHERAPEUTICS INC's free cash flow?

ARTIVA BIOTHERAPEUTICS INC (ARTV) generated -$79.3M in free cash flow during fiscal year 2025. This represents a -42.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ARTIVA BIOTHERAPEUTICS INC's operating cash flow?

ARTIVA BIOTHERAPEUTICS INC (ARTV) generated -$76.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are ARTIVA BIOTHERAPEUTICS INC's total assets?

ARTIVA BIOTHERAPEUTICS INC (ARTV) had $130.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are ARTIVA BIOTHERAPEUTICS INC's capital expenditures?

ARTIVA BIOTHERAPEUTICS INC (ARTV) invested $2.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does ARTIVA BIOTHERAPEUTICS INC spend on research and development?

ARTIVA BIOTHERAPEUTICS INC (ARTV) invested $69.5M in research and development during fiscal year 2025.

What is ARTIVA BIOTHERAPEUTICS INC's current ratio?

ARTIVA BIOTHERAPEUTICS INC (ARTV) had a current ratio of 8.61 as of fiscal year 2025, which is generally considered healthy.

What is ARTIVA BIOTHERAPEUTICS INC's debt-to-equity ratio?

ARTIVA BIOTHERAPEUTICS INC (ARTV) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ARTIVA BIOTHERAPEUTICS INC's return on assets (ROA)?

ARTIVA BIOTHERAPEUTICS INC (ARTV) had a return on assets of -64.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ARTIVA BIOTHERAPEUTICS INC's cash runway?

Based on fiscal year 2025 data, ARTIVA BIOTHERAPEUTICS INC (ARTV) had $26.7M in cash against an annual operating cash burn of $76.8M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is ARTIVA BIOTHERAPEUTICS INC's Piotroski F-Score?

ARTIVA BIOTHERAPEUTICS INC (ARTV) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ARTIVA BIOTHERAPEUTICS INC's earnings high quality?

ARTIVA BIOTHERAPEUTICS INC (ARTV) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is ARTIVA BIOTHERAPEUTICS INC?

ARTIVA BIOTHERAPEUTICS INC (ARTV) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.